If you are not happy with the results below please do another search
Gilead’s Trodelvy gives Enhertu a run for its money in metastatic breast cancer Published: Aug 16, 2022 By Alex Keown BioSpace Weeks after AstraZeneca and Daiichi Sankyo were able to move the bar in the treatment of metastatic breast cancer with Enhertu, Gilead Sciences is answering that challenge with Trodelvy. On Monday, Gilead posted what […]
On a collaboration streak, Merck is pouring a potential $3.5 billion into a partnership with circular RNA company Orna Therapeutics to develop and commercialize multiple oncology and infectious disease programs.
The U.S. government said on Monday it will provide states with up to 442,000 doses of Bavarian Nordic’s Jynneos vaccine to combat the outbreak of monkeypox disease.
The U.S. Food and Drug Administration (FDA) adopted a final rule on Tuesday to create a new category of over-the-counter hearing aids that can be sold directly to millions of Americans.
Tuesday morning saw the FDA acceptance of a supplemental New Drug Application (sNDA) and supplemental Biologics License Application (sBLA) for three industry powerhouses.
South Korea agreed on Tuesday to expand its global health partnership with the foundation set up by Microsoft Corp. (MSFT.O) co-founder and philanthropist Bill Gates.
Inhibrx Inc. announced that the European Commission (“EC”), based on a positive opinion issued by the European Medicines Agency (“EMA”), has granted orphan medicinal product designation to INBRX-109 for the treatment of chondrosarcoma.
The United Kingdom’s COVID booster campaign is set to kick off this September, after the country became the first in the world to approve an Omicron-adapted shot.
This latest leadership hire further advances the agency’s expanding health offering under its connected brands positioning.
AstraZeneca said a late-stage trial had confirmed the benefit of breast cancer drug Enhertu in patients with an advanced form of the disease who had been previously treated with another therapy.